Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

NYSE - LSE

CMSD	-0.1%	20.15	$
CMSC	-0.35%	20.05	$
RBGPF	0%	75.17	$
RIO	0.68%	83.73	$
BCE	-1.9%	21.62	$
BCC	-5%	70.24	$
GSK	-0.16%	50.33	$
NGG	-3.33%	83.15	$
AZN	-0.23%	186.43	$
BTI	-3.6%	60.89	$
JRI	1.81%	11.63	$
RELX	-3.19%	40.17	$
RYCEF	0.3%	16.43	$
VOD	-2.37%	15.58	$
BP	-0.38%	44.53	$

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

BOULEVARD 22.12.2025

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.

Text size:

The FCA has notified the Company that the admission hearing has been scheduled for the earliest available date being 5 January 2026, with admission expected to occur on or around 8.00 a.m. on 6 January 2026.

All other details outlined in the Company's announcement of 18 December 2025 remain unchanged.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[email protected]
Peter Redmond, Director	[email protected]
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
AlbR Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

Y.Nakamura--AMWN

American Marconi Wireless News - Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

Featured

Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament

InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 09

Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert

George and Amal Clooney attend New York political-comedy reading